ClinicalTrials.gg

Program

TCR1672

A development code. Also written as “TCR1672 tablet”.

In Sino Biopharmaceutical's pipeline, P2X3拮抗剂. Its studies are mostly in Chronic Cough, led by Sino Biopharmaceutical.

Furthest: phase 2, since Dec 15, 20231 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 2since Dec 15, 2023Dec 15, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TCR1672, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2023First study: phase 2 study in Chronic CoughFirst studyNCT06213363 · 72 planned

TargetBeta

“P2X3拮抗剂”the company's pipeline, read by Claude · source

Other programs on P2RX3

ProgramCompanyFurthest phaseStudies
camlipixantGlaxoSmithKlinephase 316

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06213363Chronic Cough2Not yet recruitingOct 202472

How it is read

Names in the registry

  • “TCR1672 tablet”, 1 entry

Codes read as this program: TCR1672.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.